NASDAQ:RNA

Avidity Biosciences Stock Forecast, Price & News

$23.75

-0.21 (-0.88 %)

(As of 09/20/2021 03:59 PM ET)

Add

Compare

Today's Range

$22.99

▼

$24.93

50-Day Range

$18.16

▼

$24.91

52-Week Range

$17.58

▼

$36.04

Volume17,467 shs

Average Volume336,847 shs

Market Capitalization$894.66 million

P/E RatioN/A

Dividend YieldN/A

Beta1.53

30 days | 90 days | 365 days | Advanced Chart

Receive RNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

About Avidity Biosciences

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.

Avidity Biosciences (NASDAQ:RNA) Trading 6.6% Higher
September 17, 2021 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Down to $23.92
September 14, 2021 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Shares Down 6.8%
September 10, 2021 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Shares Up 5.6%
September 8, 2021 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Up to $19.24
September 7, 2021 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Research Coverage Started at Evercore ISI
September 7, 2021 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Down to $22.84
September 1, 2021 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Sees Strong Trading Volume
August 30, 2021 | americanbankingnews.com

Avidity Biosciences Inc.
August 25, 2021 | barrons.com

European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001
August 24, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RNA
Previous Symbol
CUSIPN/A
CIK1574111
Webwww.aviditybiosciences.com
Phone858-401-7900
Employees82
Year FoundedN/A

Sales & Book Value

Annual Sales$6.79 million
Price / Sales131.76
Cash FlowN/A
Price / Cash FlowN/A
Book Value$8.16 per share
Price / Book2.91

Profitability

EPS (Most Recent Fiscal Year)($2.05)
Net Income$-44,350,000.00
Net Margins-846.95%
Return on Equity-26.48%
Return on Assets-24.25%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares37,670,000
Market Cap$894.66 million
Next Earnings Date11/9/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.39 out of 5 stars

Medical Sector

177th out of 1,352 stocks

Pharmaceutical Preparations Industry

84th out of 665 stocks

3.5 Analyst's Opinion

Consensus Rating
Avidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.00, Avidity Biosciences has a forecasted upside of 79.1% from its current price of $24.01.
Amount of Analyst Coverage
Avidity Biosciences has only been the subject of 2 research reports in the past 90 days.

4.3 Community Rank

Outperform Votes
Avidity Biosciences has received 107 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Avidity Biosciences has received 59 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Avidity Biosciences has received 64.46% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Avidity Biosciences and other stocks. Vote “Outperform” if you believe RNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Avidity Biosciences does not currently pay a dividend.
Dividend Growth
Avidity Biosciences does not have a long track record of dividend growth.

4.2 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avidity Biosciences insiders have bought 2,447.72% more of their company's stock than they have sold. Specifically, they have bought $14,400,000.00 in company stock and sold $565,212.00 in company stock.
Percentage Held by Insiders
16.08% of the stock of Avidity Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.70% of the stock of Avidity Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.96) to ($3.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avidity Biosciences is -11.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avidity Biosciences is -11.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Avidity Biosciences has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Avidity Biosciences (NASDAQ:RNA) Frequently Asked Questions

Is Avidity Biosciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avidity Biosciences stock.
View analyst ratings for Avidity Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Avidity Biosciences?

Wall Street analysts have given Avidity Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avidity Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avidity Biosciences' next earnings date?

Avidity Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Avidity Biosciences.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) posted its quarterly earnings data on Sunday, August, 8th. The biotechnology company reported ($0.70) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.71) by $0.01. Avidity Biosciences had a negative trailing twelve-month return on equity of 26.48% and a negative net margin of 846.95%.
View Avidity Biosciences' earnings history.

What price target have analysts set for RNA?

4 Wall Street analysts have issued twelve-month price targets for Avidity Biosciences' shares. Their forecasts range from $36.00 to $50.00. On average, they anticipate Avidity Biosciences' share price to reach $43.00 in the next twelve months. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for Avidity Biosciences or view top-rated stocks among Wall Street analysts.

Who are Avidity Biosciences' key executives?

Avidity Biosciences' management team includes the following people:

Dr. Troy Edward Wilson, Co-Founder & Chairman (Age 52, Pay $132k)
Ms. Sarah Boyce, Pres, CEO & Director (Age 49, Pay $823.09k)
Mr. Michael F. MacLean, Chief Financial Officer (Age 55, Pay $501.34k)
Dr. Jae B. Kim FACC, M.D., Chief Medical Officer (Age 51, Pay $340.64k)
Prof. Mark E. Davis, Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s
Dr. Frank McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board (Age 71)
Mr. Joseph Baroldi, Chief Operating Officer (Age 43)
Dr. W. Michael Flanagan Ph.D., Chief Technical Officer (Age 59)
Dr. Arthur A. Levin, Chief Scientific Officer (Age 67)
Dr. John W. Wallen III, VP of Intellectual Property, Gen. Counsel & Sec. (Age 63)

Who are some of Avidity Biosciences' key competitors?

Some companies that are related to Avidity Biosciences include 23andMe (ME), Karuna Therapeutics (KRTX), Prothena (PRTA), Emergent BioSolutions (EBS), Nektar Therapeutics (NKTR), Insmed (INSM), ALX Oncology (ALXO), Cryoport (CYRX), PTC Therapeutics (PTCT), Amicus Therapeutics (FOLD), Zentalis Pharmaceuticals (ZNTL), Apellis Pharmaceuticals (APLS), Intra-Cellular Therapies (ITCI), Agios Pharmaceuticals (AGIO) and Cytokinetics (CYTK).
View all of RNA's competitors.

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.02%), BlackRock Inc. (7.18%), Price T Rowe Associates Inc. MD (6.73%), Federated Hermes Inc. (5.23%), State Street Corp (3.57%) and Vanguard Group Inc. (3.38%). Company insiders that own Avidity Biosciences stock include Arthur A Levin and Rtw Investments, Lp.
View institutional ownership trends for Avidity Biosciences.

Which institutional investors are selling Avidity Biosciences stock?

RNA stock was sold by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC, Goldman Sachs Group Inc., Millennium Management LLC, Morgan Stanley, Morgan Stanley, FMR LLC, Acuta Capital Partners LLC, and Wells Fargo & Company MN.
View insider buying and selling activity for Avidity Biosciences or view top insider-selling stocks.

Which institutional investors are buying Avidity Biosciences stock?

RNA stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Marshall Wace North America L.P., Federated Hermes Inc., Balyasny Asset Management LLC, Victory Capital Management Inc., Citigroup Inc., PDT Partners LLC, and Principal Financial Group Inc..
View insider buying and selling activity for Avidity Biosciences or or view top insider-buying stocks.

How do I buy shares of Avidity Biosciences?

Shares of RNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avidity Biosciences' stock price today?

One share of RNA stock can currently be purchased for approximately $23.75.

How much money does Avidity Biosciences make?

Avidity Biosciences has a market capitalization of $894.66 million and generates $6.79 million in revenue each year. The biotechnology company earns $-44,350,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

How many employees does Avidity Biosciences have?

Avidity Biosciences employs 82 workers across the globe.

What is Avidity Biosciences' official website?

The official website for Avidity Biosciences is www.aviditybiosciences.com.

Where are Avidity Biosciences' headquarters?

Avidity Biosciences is headquartered at 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037.

How can I contact Avidity Biosciences?

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The biotechnology company can be reached via phone at 858-401-7900 or via email at [email protected].

This page was last updated on 9/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here